Merck & Company Inc

MRK

New York Stock Exchange. Currency in USD

86.78 -0.73 ( -0.83% )

Real time prices: September 23

Market Cap.
219.84B
Beta (5Y monthly)
0.34
Price/Earnings
11.47
EPS (TTM)
7.56
Forward Dividend
2.76 (3.21%)
Ex-Dividend Date
Sep 15, 2022
Volume
9.04M
1y Target Est.
100.85
Day's Range
86.09
-
88.01
52 Week's Range
71.50
-
95.72

Historical Summary

Performance
EPS growth
Share Buybacks

About Merck & Company Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.merck.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.53B
Employees
67000
Address
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Latest news

Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris

Merck (MRK) gets a favorable ruling from a district court of West Virginia in two...
By Zacks Investment Research - 1 day ago

Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe....
By Zacks Investment Research - 1 day ago

My Take: 4 Strong Growth Stocks to Buy This Week
My Take: 4 Strong Growth Stocks to Buy This Week

Quality and resiliency shine through when trouble starts setting in.
By The Motley Fool - 1 day ago

Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy,...
By Zacks Investment Research - 2 days ago

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth...
By Zacks Investment Research - 2 days ago

Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose

Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of...
By Zacks Investment Research - 3 days ago

3 Best Dow Jones Stocks of 2022 So Far: Are They Buys Now?
3 Best Dow Jones Stocks of 2022 So Far: Are They Buys Now?

It hasn't taken huge returns to rank among the top three of the Dow this...
By The Motley Fool - 4 days ago